Acute Myeloid Leukemia (non-APL) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	surveillance
Linked regimen	`None`

ID	`IND-MPN-SECONDARY-LEUKEMIA-PREVENTION-OBSERVATION`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-AML`
Sources	`SRC-NCCN-AML-2025` `SRC-NCCN-BCELL-2025` `SRC-NCCN-MPN-2025`

Notes

STUB — alternative-track companion for MPN / secondary AML prevention. Required for §15.2 C4 ≥2-tracks invariant. Two-Co-Lead signoff queued. As with the standard track, patients with confirmed DIS-PV / DIS-ET / DIS-PMF Disease entity route through the treatment-persona MPN algorithm; this Indication targets pre-MPN- criteria driver-mutation-positive patients only.

Used By

Red flag

RF-MPN-SECONDARY-LEUKEMIA-PREVENTION - Myeloproliferative neoplasm (polycythemia vera [PV], essential thrombocythemia [ET], or p...